John Libbey Eurotext

European Journal of Dermatology

MENU

Adjuvant high-dose intravenous immunoglobulins for recalcitrant erosive oral lichen planus: mixed clinical responses Volume 28, issue 4, July-August 2018

Figures

  • Figure 1
  • Figure 2
  • Figure 3

Tables

Authors
Department of Dermatology and Allergology, Philipps University Marburg, Germany
* Reprints
a These authors contributed equally
  • Key words: intravenous immunoglobulins (IVIG), oral lichen planus, ABSIS score
  • DOI : 10.1684/ejd.2018.3370
  • Page(s) : 496-501
  • Published in: 2018

Background: Erosive oral lichen planus (OLP) is, at times, extremely difficult to treat and has a major impact on patients’ quality of life. There are only limited therapeutic options, such as topical and systemic glucocorticoids, retinoids, and immunosuppressants with considerable side effects and limited efficacy upon chronic use. Objectives: In the present individualised clinical trial, we assessed the efficacy of adjuvant intravenous immunoglobulins (IVIG; 2 g/kg/monthly cycle) in addition to the oral retinoid, acitretin, in three patients with refractory OLP over a period of two to six months. Materials & Methods: The efficacy of adjuvant IVIG treatment was evaluated using the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) which measures both extent of mucosal lesions and functional sequelae. Results: The three OLP patients showed mixed responses to adjuvant IVIG treatment, ranging from therapeutic efficacy to a lack of response to IVIG. Conclusions: In light of the observed therapeutic responses and a lack of good therapeutic options, adjuvant IVIG, although costly, warrants further investigation as a treatment option for OLP.